Fosmidomycin‐Clindamycin forPlasmodium falciparumInfections in African Children | Zendy

Steffen Borrmann | Zendy; Ayôla Akim Adégnika | Zendy; PierreBlaise Matsiegui | Zendy; Saadou Issifou | Zendy; Andreas Schindler | Zendy; Denise Patricia Mawili-Mboumba | Zendy; Thomas Baranek | Zendy; Jochen Wiesner | Zendy; Hassan Jomaa | Zendy; Peter G. Kremsner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fosmidomycin‐Clindamycin forPlasmodium falciparumInfections in African Children

Author(s) -

Steffen Borrmann,

Ayôla Akim Adégnika,

PierreBlaise Matsiegui,

Saadou Issifou,

Andreas Schindler,

Denise Patricia Mawili-Mboumba,

Thomas Baranek,

Jochen Wiesner,

Hassan Jomaa,

Peter G. Kremsner

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/381785

Subject(s) - plasmodium falciparum , clindamycin , malaria , medicine , virology , microbiology and biotechnology , biology , immunology , antibiotics

Fosmidomycin is a new antimalarial drug with a novel mechanism of action. Studies in Africa that have evaluated fosmidomycin as monotherapeutic agent demonstrated its excellent tolerance, but 3-times-daily treatment regimens of >or=4 days were required to achieve radical cure, prompting further research to identify and validate a suitable combination partner to enhance its efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research